SCM
SPRB

Stonepine Capital Management’s Spruce Biosciences SPRB Stock Holding History

Stonepine Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Buy
+28,795
New +$1.61M 0.88% 31
2026
Q1 		– Sell
-19,742
Closed -$1.72M – 100
2025
Q4 		$1.72M Buy
+19,742
New +$2.12M 1.26% 25

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Stonepine Capital Management's SPRB Position: Q2 2026 in Review

Stonepine Capital Management opened a new position in Spruce Biosciences (SPRB) in Q2 2026: 28,795 shares worth $1.55M. The stake represents 0.88% of the portfolio and ranks #31 among its holdings. This is a return to the name: Stonepine Capital Management previously reported a position in SPRB as recently as Q4 2025.

Stonepine Capital Management first reported a position in SPRB in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.72M in Q4 2025. 63 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Stonepine Capital Management held 28,795 shares of Spruce Biosciences worth $1.55M as of Q2 2026.
  • Spruce Biosciences was a new Stonepine Capital Management position in Q2 2026.
  • Spruce Biosciences made up 0.88% of Stonepine Capital Management's portfolio in Q2 2026, its #31 holding.
  • Stonepine Capital Management first reported a position in Spruce Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Stonepine Capital Management's Spruce Biosciences position peaked at $1.72M in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.